What the Research Says
The Wilt review pooled four trials with 519 men lasting 4–26 weeks. Beta-sitosterol improved urinary symptom scores and flow without reducing prostate size, but long-term safety, effectiveness and prevention of BPH complications were unknown. In the 200-person Berges trial, six-month IPSS changes were −7.4 versus −2.1 points for placebo. For a different use, a 59-trial meta-analysis of mixed plant sterols found a mean LDL reduction of 0.31 mmol/L, varying by baseline LDL, food vehicle and schedule. These results do not establish that isolated beta-sitosterol prevents cardiovascular events.

